Mimedx Group Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-20.6%projected annual EPS growth
Analyst Coverage
5analysts covering
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 29 Oct 2026 |
Monitoring Framework
Key Performance Indicators
Net Sales Quarterly59MTarget: 260000000 to 290000000
Surgical Segment Net Sales Quarterly36.4MTarget: Double-digit annual growth
Wound Segment Net Sales Quarterly22.6MTarget: Stabilization and recovery post-reimbursement reform
Gross Margin Quarterly71.0%Target: Low 70s in 2026, mid-70s by year-end
Adjusted EBITDA Quarterly-11.6MTarget: Approximately breakeven on a full year basis
Watch Items
- Medicare Administrative Contractor (MAC) Local Coverage Determination (LCD) ImplementationTrigger: Inconsistent rule enforcement or further pricing pressure on skin substitutesAction: Adjust commercial strategy, focus sales force on compliant care settings, and leverage clinical evidence
- Annualized Cost Savings ExecutionTrigger: Failure to realize the targeted $40 million in annualized savingsAction: Further streamline operations, review SG&A expenses, and optimize headcount
- EPIEFFECT and CHORIOFIX Clinical Trial ProgressTrigger: Completion of enrollment or publication of interim data from the CAMPAIGN prospective randomized controlled trialAction: Leverage clinical superiority data to secure favorable commercial and Medicare coverage
Research as of 19 Jun 2026